Bond.az White LogoBond.az Black Logo
→
EN ▾
AZENRU
ITV to elect new director on May 25Cause of death of missing architect in Istanbul revealedDiaSorin Sees 2026 Revenue Growth of 5%-6%Maven admits 238,026 new sharesFrench Rep: Sustainability Key to Affordable HousingAuthID Q1 2026 Revenue Jumps 62%Addtech Q4 2025: Robust Growth and ProfitabilityBaku to Clean 3 Lakes: Boyukshor, Zikh, KhojahasanBarclays Options Trades on Nvidia, Halliburton, SnowflakeFull Truck Alliance SWOT analysis: stock faces transformationITV to elect new director on May 25Cause of death of missing architect in Istanbul revealedDiaSorin Sees 2026 Revenue Growth of 5%-6%Maven admits 238,026 new sharesFrench Rep: Sustainability Key to Affordable HousingAuthID Q1 2026 Revenue Jumps 62%Addtech Q4 2025: Robust Growth and ProfitabilityBaku to Clean 3 Lakes: Boyukshor, Zikh, KhojahasanBarclays Options Trades on Nvidia, Halliburton, SnowflakeFull Truck Alliance SWOT analysis: stock faces transformation
Personalize
Bond.az White LogoBond.az Black Logo
AZENRU

#sab-biotherapeutics

Latest news and interesting information about sab-biotherapeutics.

Jefferies Initiates SAB Biotherapeutics with Buy
Today / 08:21
|
408

Jefferies Initiates SAB Biotherapeutics with Buy

Jefferies initiates coverage on SAB Biotherapeutics with a Buy rating and $11 target, focusing on SAB-142 diabetes therapy.

ANALYST RATINGS →
0
...